Accessibility Menu
Avalyn Pharma logo

Avalyn Pharma

(NASDAQ) AVLN

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A

Avalyn Pharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 2, 2026

AVLN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avalyn Pharma

Avalyn Pharma Inc. is a biopharmaceutical firm focused on developing inhaled pharmaceutical products for rare lung conditions. The company aims to address significant unmet medical needs in pulmonary fibrosis and various interstitial lung diseases (ILDs).

Products and Services
  • Inhaled therapies targeting rare lung diseases
  • Clinical development of innovative pharmaceutical solutions
  • Focus on improving patient outcomes in respiratory health
Growth Outlook
  • Strong market potential in the rare lung disease sector
  • Increasing demand for effective inhaled therapies
  • Commitment to advancing clinical trials and product development
Financial Highlights
  • Market capitalization of approximately $1.39 billion
  • Stock price range between $24.15 and $32.23 over the year
  • Average trading volume of 537,580 shares
Avalyn Pharma Inc. operates in a niche market with significant growth potential, particularly in the development of inhaled therapies for rare lung conditions. The company's focus on innovative solutions positions it well to meet the increasing demand for effective treatments in this area. With a solid market capitalization and a stable stock price range, Avalyn Pharma is poised for continued interest from investors. The commitment to advancing clinical trials further enhances the company's prospects, making it an intriguing option for those interested in the biopharmaceutical sector.
AI Generated • Jun 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Boston, MA 02127, US

AVLN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

35.70%

Return on Capital

N/A

Return on Assets

-57.23%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$27.91M

EBITDA

-$26.71M

Operating Cash Flow

-$29.89M

Capital Expenditure

-$318.00K

Free Cash Flow

-$30.21M

Cash & ST Invst.

$123.13M

Total Debt

$16.41M

Avalyn Pharma Performance Analysis

Avalyn Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12026-03-31N/A
Avalyn Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

50

N/A

Net Income

-$26.87M

N/A

EBITDA

-$26.71M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$123.13M

N/A

Total Debt

$16.41M

N/A

Accounts Receivable

$253.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$15.90M

N/A

Short Term Debt

$507.00K

N/A

Return on Assets

-57.23%

N/A

Return on Invested Capital

-67.73%

N/A

Free Cash Flow

-$30.21M

N/A

Operating Cash Flow

-$29.89M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,462.11-0.01%
^DJIDJI
$52,200.80-0.01%
^IXICNASDAQ
$25,548.29-0.01%
BTCBitcoin
$63,934.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
SOFISoFi Technologies
$17.28-0.00%

Questions About AVLN

What is the current price of Avalyn Pharma?

Avalyn Pharma is trading at N/A per share.

What is the 52-week range for Avalyn Pharma?

Over the past 52 weeks, Avalyn Pharma has traded between N/A and N/A.

How much debt does Avalyn Pharma have?

Avalyn Pharma total debt is unavailable.

How much cash does Avalyn Pharma have on hand?

Avalyn Pharma does not have cash on hand data available.

What is Avalyn Pharma’s dividend yield?

Avalyn Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services